Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The objective of this study was to investigate clinical and laboratory parameters that could predict which patients could maintain adequate glycemic control after switching from initial insulin therapy to oral hypoglycemic agents (OHAs) among patients with type 2 diabetes (T2D). Materials and Methods: We recruited 275 patients with T2D who had been registered in 3 cohorts of initiated insulin therapy and followed up for 33 months. The participants were divided into 2 groups according to whether they switched from insulin to OHAs (Group I) or not (Group II), and Group I was further classified into 2 sub-groups: maintenance on OHAs (Group IA) or resumption of insulin (Group IB). Results: Of 275 patients with insulin initiation, 63% switched to OHAs (Group I) and 37% continued insulin (Group II). Of these, 44% were in Group IA and 19% in Group IB. The lowest tertile of baseline postprandial C-peptide-to-glucose ratio (PCGR), higher insulin dose at switching to OHAs, and higher HbA1c level at 6 months after switching to OHAs were all associated with OHA failure(Group IB; p=0.001, 0.046, and 0.014, respectively). The lowest tertile of PCGR was associated with ultimate use of insulin (Group IB and Group II; p=0.029). Conclusion: Higher baseline level of PCGR and lower HbA1c levels at 6 months after switching to OHAs may be strong predictors for the successful maintenance of OHAs after switching from insulin therapy in Korean patients with T2D.
Abstract
Purpose: The objective of this study was to investigate clinical and laboratory parameters that could predict which patients could maintain adequate glycemic control after switching from initial insulin therapy to oral hypoglycemic agents (OHAs) among patients with type 2 diabetes (T2D). Materials and Methods: We recruited 275 patients with T2D who had been registered in 3 cohorts of initiated insulin therapy and followed up for 33 months. The participants were divided into 2 groups according to whether they switched from insulin to OHAs (Group I) or not (Group II), and Group I was further classified into 2 sub-groups: maintenance on OHAs (Group IA) or resumption of insulin (Group IB). Results: Of 275 patients with insulin initiation, 63% switched to OHAs (Group I) and 37% continued insulin (Group II). Of these, 44% were in Group IA and 19% in Group IB. The lowest tertile of baseline postprandial C-peptide-to-glucose ratio (PCGR), higher insulin dose at switching to OHAs, and higher HbA1c level at 6 months after switching to OHAs were all associated with OHA failure(Group IB; p=0.001, 0.046, and 0.014, respectively). The lowest tertile of PCGR was associated with ultimate use of insulin (Group IB and Group II; p=0.029). Conclusion: Higher baseline level of PCGR and lower HbA1c levels at 6 months after switching to OHAs may be strong predictors for the successful maintenance of OHAs after switching from insulin therapy in Korean patients with T2D.
참고문헌 (31)
- DeFronzo RA, "Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM", Diabetes, 37, pp.667~687 (1988)
- Kahn SE, "The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes", Diabetologia, 46, pp.3~19 (2003)
- 김유정, "Effect of Socio-Economic Status on the Prevalence of Diabetes", Yonsei Medical Journal, 56(3), pp.641~647 (2015), 연세대학교의과대학[DOI]
- Weng J, "Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial", Lancet, 371, pp.1753~1760 (2008)
- Kramer CK, "Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis", Lancet Diabetes Endocrinol, 1, pp.28~34 (2013)
- Tibaldi J, "Why, when and how to initiate insulin therapy in patients with type 2 diabetes", Int J Clin Pract, 61, pp.633~644 (2007)
- Hye Jin Yoo, "Safety and Efficacy of Modern Insulin Analogues", Diabetes & Metabolism Journal, 37(3), pp.181~ (2013), Korean Diabetes Association (KAMJE)[DOI]
- Riddle MC, "The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients", Diabetes Care, 26, pp.3080~3086 (2003)
- Holman RR, "Three-year effcacy of complex insulin regimens in type 2diabetes", N Engl J Med, 361, pp.1736~1747 (2009)
- Janka HU, "Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes", Diabetes Care, 28, pp.254~259 (2005)
- Hwang YC, "The glycemic effcacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: subanalysis from the A(1)chieve(®) study", Int J Clin Pract, 68, pp.1338~1344 (2014)
- Lee YH, "Predictive characteristics of patients achieving glycaemic control with insulin after sulfonylurea failure", Int J Clin Pract, 65, pp.1076~1084 (2011)
- Eun Yeong Choe, "Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus", Diabetes & Metabolism Journal, 36(3), pp.230~ (2012), Korean Diabetes Association (KAMJE)[DOI]
- Lee YH, "Higher morning to evening ratio in total dose of twice-daily biphasic insulin analog might be effective in achieving glucose control in patients with poorly controlled type 2 diabetes", Diabetes Technol Ther, 14, pp.508~514 (2012)
- Jung CH, "The optimal morning:evening ratio in total dose of twice-daily biphasic insulin analogue in poorly controlled Type 2 diabetes: a 24-week multi-centre prospective, randomized controlled, open-labelled clinical study.", Diabet Med, 31, pp.68~75 (2014)
- 김원진, "The Glycated Albumin to Glycated Hemoglobin Ratio Might Not Be Associated with Carotid Atherosclerosis in Patients with Type 1 Diabetes", Diabetes and Metabolism Journal, 38(6), pp.456~463 (2014), 대한당뇨병학회[DOI]
- Yamada Y, "SUIT, secretory units of islets in transplantation:An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes", Diabetes Res Clin Pract, 74, pp.222~226 (2006)
- Lee EY, "Postprandial C-peptide to glucose ratio as a predictor of β-cell function and its usefulness for staged management of type 2 diabetes", J Diabetes Investig, 5, pp.517~524 (2014)
- Ito R, "Teneligliptin, a dipeptidyl peptidase-4 inhibitor, improves earlyphase insulin secretion in drug-naïve patients with type 2 diabetes", Drugs R D, 15, pp.245~251 (2015)
- 박소윤, "Triglyceride Is a Useful Surrogate Marker for Insulin Resistance in Korean Women with Polycystic Ovary Syndrome", Yonsei Medical Journal, 56(3), pp.785~792 (2015), 연세대학교의과대학[DOI]
- World Health Organization, "The Asia Pacific perspective: redefining obesity and its treatment" (2000), Health Communications Australia
- Steil GM, "Evaluation of insulin sensitivity and beta-cell function indexes obtained from minimal model analysis of a meal tolerance test", Diabetes, 53, pp.1201~1207 (2004)
- Mari A, "A model for glucose control of insulin secretion during 24 h of free living", Diabetes, 50(Suppl 1), pp.S164~S168 (2001)
- Kim DJ, "Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus", Metabolism, 50, pp.590~593 (2001)
- Törn C, "C-peptide and autoimmune markers in diabetes", Clin Lab, 49, pp.1~10 (2003)
- Meier JJ, "Functional assessment of pancreatic beta-cell area in humans", Diabetes, 58, pp.1595~1603 (2009)
- Drucker DJ, "The incretin system: glucagon-like pep-tide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes", Lancet, 368, pp.1696~1705 (2006)
- Fleetcroft R, "Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysis", BMC Health Serv Res, 14, pp.414~ (2014)
- Shim WS, "Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes", Eur J Endocrinol, 155, pp.615~622 (2006)
- Saisho Y, "Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes", Endocr J, 58, pp.315~322 (2011)
- Glaser B, "Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes", Diabetes Obes Metab, 1, pp.67~74 (1999)